This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Drs. Glick and Marder Reply

Ira D. Glick, MD, and Stephen R. Marder, MD

Published: March 15, 2006

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: The authors of the letter raise a number of interesting issues.

They expressed a concern that the study1 was biased toward quetiapine because of the open-label design and the use of a dose of quetiapine that was higher than the equivalent dose of haloperidol decanoate. We used an open-label design with blinded ratings in order to increase the external validity of the study.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 67

Quick Links: Psychiatry

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...